van Lierop, ZYGJ;
Toorop, AA;
Coerver, EME;
Willemse, EAJ;
Strijbis, EMM;
Kalkers, NF;
Moraal, B;
... van Kempen, ZLE; + view all
(2021)
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.
Multiple Sclerosis Journal
, 7
(2)
10.1177/20552173211013831.
Preview |
Text
Barkhof_20552173211013831.pdf - Published Version Download (882kB) | Preview |
Abstract
Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.
| Type: | Article |
|---|---|
| Title: | Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/20552173211013831 |
| Publisher version: | http://dx.doi.org/10.1177/20552173211013831 |
| Language: | English |
| Additional information: | https://creativecommons.org/licenses/by/4.0/Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| Keywords: | Multiple sclerosis, natalizumab, ocrelizumab, JC virus, disease activity, progressive multifocal leukoencephalopathy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Brain Repair and Rehabilitation |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10129294 |
Archive Staff Only
 |
View Item |
